Lung Biotechnology Inc.

Lung Llc, a Wholly Owned Subsidiary of United Therapeutics Corporation

Monika Rieger

Thomas Schmehl

Tobias Gessler

The invention relates to liposomes for pulmonary application, advantageously comprising at least one first and at least one second phospholipid, cholesterol, and at least one active substance and/or colorant, wherein the first phospholipid is a phosphatidylcholine, preferably DSPC, and the second phospholipid is a phosphatidylcholine or an ethanolamine, preferably selected from the group DMPC, DPPC, DPPE. It is thereby advantageous if the first and the second phospholipid are present at a molar ratio of 0.5:1 to 10:1, preferably at a ratio of 6:1 to 2:1, in particular preferably at a ratio of 3:1. It is further advantageous if the molar ratio between phospholipids and cholesterol is between 10:1 and 1:1, preferably between 6:1 and 3:1, in particular preferably 4:1. The second phospholipid is further preferably DMPC or DPPE, in particular preferably DPPE. The size of the liposomes is advantageously between 0.05 &#x3bc;m and 5 &#x3bc;m, preferably between 0.2 &#x3bc;m and 2.0 &#x3bc;m, and the median aerodynamic mass diameter of aerosol particles comprising the liposomes is between 1 &#x3bc;m and 6 &#x3bc;m, preferably between 1.5 &#x3bc;m and 5 &#x3bc;m, in particular preferably between 2 &#x3bc;m and 4.5 &#x3bc;m. It is further in particular advantageous if the liposomes comprise an atomization stability of greater than 50%, preferably greater than 75%, in particular preferably greater than 80%, and if the transition temperature is greater than 37&#xb0; C., preferably greater than 45&#xb0; C., in particular preferably greater than 50&#xb0; C.

Growing community of inventors

Spiesen-Elversberg, Germany

Monika Rieger